|
WO02079415A2
|
|
Reducing the immunogenicity of fusion proteins
|
|
WO0202143A2
|
|
Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
|
|
WO0158957A2
|
|
Enhancing the circulating half-life of antibody-based fusion proteins
|
|
CN1382158A
|
|
Multiple cytokine-antibody complexes
|
|
CA2372400A1
|
|
Expression and export of interferon-alpha proteins as fc fusion proteins
|
|
BR0007414A
|
|
Expression and export of anti-obesity proteins as fc fusion proteins
|
|
BR9913331A
|
|
Expression and export of angiogenesis inhibitors as immunofusins
|
|
SK782002A3
|
|
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
BR9909677A
|
|
Intensification of immune responses, mediated by antibody-cytokine fusion protein, through co-administration with prostaglandin inhibitor
|
|
BR9909583A
|
|
Increased immune response mediated by an antibody-cytokine fusion protein by coadministration with angiogenesis inhibitor
|
|
AU2784299A
|
|
Enhancing the circulating half-life of antibody-based fusion proteins
|
|
AU1716099A
|
|
Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
|
